BRPI0513673A - método para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, veìculo utilizado na administração enteral de compostos biologicamente ativos, composição farmacêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato - Google Patents
método para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, veìculo utilizado na administração enteral de compostos biologicamente ativos, composição farmacêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfatoInfo
- Publication number
- BRPI0513673A BRPI0513673A BRPI0513673-3A BRPI0513673A BRPI0513673A BR PI0513673 A BRPI0513673 A BR PI0513673A BR PI0513673 A BRPI0513673 A BR PI0513673A BR PI0513673 A BRPI0513673 A BR PI0513673A
- Authority
- BR
- Brazil
- Prior art keywords
- biologically active
- active compounds
- transport
- pharmaceutical composition
- effective amount
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 title abstract 2
- 239000012992 electron transfer agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
MéTODO PARA AUMENTAR A EFICáCIA E O TRANSPORTE DOS COMPOSTOS BIOLOGICAMENTE ATIVOS ENTERALMENTE ADMINISTRADOS, VEìCULO UTILIZADO NA ADMINISTRAçãO ENTERAL DE COMPOSTOS BIOLOGICAMENTE ATIVOS, COMPOSIçAO FARMACêUTICA E USO DE UMA QUANTIDADE EFICAZ DE UM OU MAIS DERIVADOS DE FOSFATO Trata-se de um veículo para ser utilizado na administração enteral de compostos biologicamente ativos, sendo que o dito veículo compreende uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004904366A AU2004904366A0 (en) | 2004-08-03 | Carrier for enteral administration | |
AU2004904366 | 2004-08-03 | ||
AU2005901723 | 2005-04-07 | ||
AU2005901723A AU2005901723A0 (en) | 2005-04-07 | Carrier for enteral administration | |
PCT/AU2005/001159 WO2006012692A1 (en) | 2004-08-03 | 2005-08-03 | Carrier for enteral administration |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0513673A true BRPI0513673A (pt) | 2008-05-13 |
BRPI0513673B1 BRPI0513673B1 (pt) | 2019-02-26 |
BRPI0513673B8 BRPI0513673B8 (pt) | 2021-07-27 |
Family
ID=35786821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513673A BRPI0513673B8 (pt) | 2004-08-03 | 2005-08-03 | método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090004166A1 (pt) |
EP (2) | EP2269650A3 (pt) |
JP (1) | JP5198858B2 (pt) |
KR (1) | KR101238703B1 (pt) |
AT (1) | ATE494911T1 (pt) |
BR (1) | BRPI0513673B8 (pt) |
CA (1) | CA2575587C (pt) |
DE (1) | DE602005025883D1 (pt) |
IL (1) | IL180772A0 (pt) |
MX (1) | MX2007001356A (pt) |
NZ (1) | NZ553476A (pt) |
RU (1) | RU2377019C2 (pt) |
WO (1) | WO2006012692A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002040034A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd. | Complexes of phosphate derivatives |
AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
MXPA04000654A (es) | 2001-07-27 | 2004-03-19 | Vital Health Sciences Pty Ltd | Terapia dermica usando derivados de fosfato de agente de transferencia de electrones. |
AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
WO2004064831A1 (en) * | 2003-01-17 | 2004-08-05 | Vital Health Sciences Pty Ltd | Compounds having anti-proliferative properties |
AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
CA2557354C (en) | 2004-03-03 | 2013-05-07 | Vital Health Sciences Pty Ltd. | Alkaloid formulations |
US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
NZ565049A (en) | 2005-06-17 | 2012-02-24 | Vital Health Sciences Pty Ltd | A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
EP2531047A4 (en) * | 2010-02-05 | 2014-03-19 | Phosphagenics Ltd | CARRIER WITH AN UNINUTRALIZED TOCOPHERYL PHOSPHATE |
EP2531219A4 (en) * | 2010-02-05 | 2015-01-14 | Phosphagenics Ltd | SUPPORT COMPOSITION |
EP2552486B1 (en) | 2010-03-30 | 2020-08-12 | Phosphagenics Limited | Transdermal delivery patch |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
JP6882321B2 (ja) | 2015-12-09 | 2021-06-02 | フォスファージニクス リミテッド | 医薬製剤 |
WO2017214497A1 (en) | 2016-06-10 | 2017-12-14 | Clarity Cosmetics Inc. | Non-comedogenic hair and scalp care formulations and method for use |
AU2017381395A1 (en) | 2016-12-21 | 2019-06-20 | Phosphagenics Limited | Process |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2667479A (en) * | 1951-01-30 | 1954-01-26 | Merck & Co Inc | Benzimidazole phosphate |
US3127434A (en) * | 1959-10-20 | 1964-03-31 | Hoffmann La Roche | Dihydrovitamin k monophosphate compounds and preparation thereof |
US3607765A (en) * | 1968-11-29 | 1971-09-21 | Colgate Polmolive Co | Detergent softener compositions |
US4444755A (en) * | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
US4977282A (en) * | 1984-04-17 | 1990-12-11 | Henkel Corporation | Production of d-alpha-tocopherol from natural plant sources |
US4603142A (en) * | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
JPH01228920A (ja) * | 1988-03-09 | 1989-09-12 | Kuraray Co Ltd | 吸収促進剤 |
JPH01274830A (ja) * | 1988-04-28 | 1989-11-02 | Asahi Denka Kogyo Kk | 安全で且つ高度な界面活性を有する脂質組成物 |
US6028105A (en) * | 1989-04-06 | 2000-02-22 | Nigra; Thomas P. | Topical drug delivery composition and method |
FR2657526B1 (fr) * | 1990-01-31 | 1994-10-28 | Lvmh Rech | Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues. |
EP0543417A1 (en) * | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
JP3207494B2 (ja) * | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | 水性懸濁製剤 |
US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
FR2714595B1 (fr) * | 1993-12-30 | 1996-02-02 | Oreal | Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement. |
DE4444238A1 (de) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
KR100387156B1 (ko) * | 1995-04-21 | 2003-10-11 | 세키스이가가쿠 고교가부시키가이샤 | 피부질환치료용외용제 |
US5665389A (en) * | 1995-05-24 | 1997-09-09 | University Of Maryland At Baltimore | Oral dosage composition for intestinal delivery and method of treating diabetes |
US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6727280B2 (en) * | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
JP4608031B2 (ja) * | 1997-03-13 | 2011-01-05 | ヘキサル アーゲー | アミノ酸/シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化 |
IT1294748B1 (it) * | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | Formulazione per un dispositivo transdermico |
KR20010033811A (ko) * | 1997-12-31 | 2001-04-25 | 토마스 안 빅토리아 | 2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법 |
US6461623B2 (en) * | 1998-04-13 | 2002-10-08 | Kao Corporation | Cosmetic composition |
AUPQ037499A0 (en) * | 1999-05-14 | 1999-06-10 | Swig Pty Ltd | Improved process for phosphorylation and compounds produced by this method |
AUPP829399A0 (en) * | 1999-01-25 | 1999-02-18 | Swig Pty Ltd | Recovery for chroman derivatives |
US6156354A (en) * | 1999-01-29 | 2000-12-05 | Brandeis University | Hyper-absorption of vitamin E dispersed in milks |
AU5594700A (en) * | 1999-06-01 | 2000-12-18 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6346544B2 (en) * | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
AU2001247739A1 (en) * | 2000-03-24 | 2001-10-08 | Baker Norton Pharmaceuticals, Inc. | Uses of metal salts to stabilize taxane-based compositions |
US6361800B1 (en) * | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
US6485950B1 (en) * | 2000-07-14 | 2002-11-26 | Council Of Scientific And Industrial Research | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions |
KR100365070B1 (ko) * | 2000-08-29 | 2002-12-16 | 주식회사 태평양 | 토코페롤 유도체 및 그의 제조방법 |
WO2002026238A1 (en) * | 2000-09-26 | 2002-04-04 | Vital Health Sciences Pty Ltd. | Phosphate derivative supplements |
WO2002040034A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd. | Complexes of phosphate derivatives |
AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
CA2426852C (en) | 2000-11-14 | 2010-01-26 | Vital Health Sciences Pty Ltd | Formulation containing phosphate derivatives of electron transfer agents |
WO2002047680A2 (en) * | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
TW576859B (en) * | 2001-05-11 | 2004-02-21 | Shipley Co Llc | Antireflective coating compositions |
MXPA04000654A (es) * | 2001-07-27 | 2004-03-19 | Vital Health Sciences Pty Ltd | Terapia dermica usando derivados de fosfato de agente de transferencia de electrones. |
AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
MXPA04001779A (es) * | 2001-09-26 | 2004-05-31 | Vital Health Sciences Pty Ltd | Modulacion de almacenamiento de vitamina. |
AU2002951045A0 (en) * | 2002-08-27 | 2002-09-12 | Vital Health Sciences Pty Ltd | Method of supplementing nascent endogenous storage forms |
JP4370451B2 (ja) * | 2001-09-28 | 2009-11-25 | 大塚製薬株式会社 | 医薬組成物 |
CA2466536C (en) * | 2001-12-13 | 2012-02-07 | Vital Health Sciences Pty Ltd | Transdermal transport of compounds |
US20030220301A1 (en) * | 2002-02-14 | 2003-11-27 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
US7074825B2 (en) * | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
KR20050003417A (ko) * | 2002-05-09 | 2005-01-10 | 쇼와 덴코 가부시키가이샤 | 피부 미백용 외용제 |
AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US7399784B2 (en) * | 2002-11-26 | 2008-07-15 | Children's Hospital & Research Center At Oakland | Tocopherol and tocotrienol anti-obesity medicaments |
US6645514B1 (en) * | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
WO2004064831A1 (en) * | 2003-01-17 | 2004-08-05 | Vital Health Sciences Pty Ltd | Compounds having anti-proliferative properties |
AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
AU2003901813A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Pharmaceutical derivatives |
AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
US7207669B2 (en) * | 2003-12-19 | 2007-04-24 | Arizona Chemical Company | Jet printing inks containing polymerized fatty acid-based polyamides |
PT1718258E (pt) * | 2004-02-23 | 2009-06-16 | Euro Celtique Sa | Dispositivo de administração transdérmica de opióides com resistência ao abuso |
CA2557354C (en) * | 2004-03-03 | 2013-05-07 | Vital Health Sciences Pty Ltd. | Alkaloid formulations |
US20060120979A1 (en) * | 2004-12-02 | 2006-06-08 | Joel Rubin | Skin care composition comprising hydroquinone and a substantially anhydrous base |
US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
WO2006092024A1 (en) * | 2005-03-03 | 2006-09-08 | Vital Health Sciences Pty Ltd | Compounds having anti-cancer properties |
US20060228395A1 (en) * | 2005-04-11 | 2006-10-12 | Robert Lamb | Vitamin E phosphate/phosphatidylcholine liposomes to protect from or ameliorate cell damage |
NZ565049A (en) * | 2005-06-17 | 2012-02-24 | Vital Health Sciences Pty Ltd | A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
KR100764679B1 (ko) * | 2005-07-22 | 2007-10-09 | 익수제약 주식회사 | 파록세틴을 함유하는 경피투여용 패취제 |
US7446096B2 (en) * | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
BRPI0621081A2 (pt) * | 2005-12-23 | 2011-11-29 | Vital Health Sciences Pty Ltd | método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos |
FR2921259B1 (fr) * | 2007-09-26 | 2015-02-13 | Lvmh Rech | Utilisation cosmetique du phosphate de tocopherol comme agent anti-vieillissement de la peau |
EP2113242A1 (en) * | 2008-05-02 | 2009-11-04 | Pangaea Laboratories Limited | Antioxidant for use in cosmetic, medicated and pharmaceutical preparations |
-
2005
- 2005-08-03 EP EP10181143A patent/EP2269650A3/en not_active Withdrawn
- 2005-08-03 JP JP2007524135A patent/JP5198858B2/ja active Active
- 2005-08-03 CA CA2575587A patent/CA2575587C/en active Active
- 2005-08-03 DE DE602005025883T patent/DE602005025883D1/de active Active
- 2005-08-03 NZ NZ553476A patent/NZ553476A/en unknown
- 2005-08-03 BR BRPI0513673A patent/BRPI0513673B8/pt active IP Right Grant
- 2005-08-03 EP EP05768314A patent/EP1778289B1/en active Active
- 2005-08-03 KR KR1020077002182A patent/KR101238703B1/ko not_active IP Right Cessation
- 2005-08-03 RU RU2007102034/15A patent/RU2377019C2/ru active
- 2005-08-03 AT AT05768314T patent/ATE494911T1/de not_active IP Right Cessation
- 2005-08-03 WO PCT/AU2005/001159 patent/WO2006012692A1/en active Application Filing
- 2005-08-03 US US11/572,864 patent/US20090004166A1/en not_active Abandoned
- 2005-08-03 MX MX2007001356A patent/MX2007001356A/es active IP Right Grant
-
2007
- 2007-01-18 IL IL180772A patent/IL180772A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2575587C (en) | 2014-06-17 |
RU2377019C2 (ru) | 2009-12-27 |
DE602005025883D1 (de) | 2011-02-24 |
MX2007001356A (es) | 2007-04-23 |
JP5198858B2 (ja) | 2013-05-15 |
BRPI0513673B8 (pt) | 2021-07-27 |
BRPI0513673B1 (pt) | 2019-02-26 |
CA2575587A1 (en) | 2006-02-09 |
RU2007102034A (ru) | 2008-09-10 |
KR20070040379A (ko) | 2007-04-16 |
JP2008508326A (ja) | 2008-03-21 |
NZ553476A (en) | 2010-06-25 |
KR101238703B1 (ko) | 2013-03-04 |
EP2269650A2 (en) | 2011-01-05 |
IL180772A0 (en) | 2007-06-03 |
EP1778289A1 (en) | 2007-05-02 |
WO2006012692A1 (en) | 2006-02-09 |
EP2269650A3 (en) | 2012-05-16 |
ATE494911T1 (de) | 2011-01-15 |
EP1778289A4 (en) | 2008-02-13 |
EP1778289B1 (en) | 2011-01-12 |
US20090004166A1 (en) | 2009-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513673A (pt) | método para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, veìculo utilizado na administração enteral de compostos biologicamente ativos, composição farmacêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato | |
BR0313575C1 (pt) | Método para melhorar a eficácia e/ou transporte transdermal de nutrientes e nutricêuticos topicamente administrados, veìculo para ser utilizado da administração tópica ou transdermal de nutrientes ou nutricêuticos, composição nutricêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons junto com outros excipientes | |
PE20050438A1 (es) | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos | |
BR0016496A (pt) | Sistema de armazenamento para medicamentos em forma de pó e inalador equipado para isso | |
AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
BR0313424A (pt) | Forma de dosagem e processo para a preparação de uma forma de dosagem | |
BRPI0508125A (pt) | formulação de alcalóide, método para melhorar a eficácia de um alcalóide, uso do produto da reação de um ou mais alcalóides com um mais derivados de fosfato de um ou mais agentes de transferência de elétrons, junto com excipientes e composição farmacêutica | |
UY26496A1 (es) | Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco | |
CL2010000816A1 (es) | Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06) | |
BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
DE60312523D1 (de) | Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit | |
BRPI0414000B8 (pt) | composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica | |
BRPI0518266B8 (pt) | medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular | |
BRPI0510684A (pt) | composições para adiministração tópica ou transdérmica de agente anticolinérgico ou antiespasmódico e uso dos respectivos compostos | |
AR033688A1 (es) | Composicion parenteral reconstituible | |
BR0311460A (pt) | Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente | |
BR9810729A (pt) | Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante | |
FI964285A (fi) | Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet | |
AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
ME00624B (me) | Nova primjena docetaksela za liječenje hepatoma | |
UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
CO5550418A2 (es) | Formulaciones antihistaminicas para formas de dosificacion de capsula blanda | |
AR040287A1 (es) | Plataforma para formulaciones transdermicas (pft) | |
PA8496701A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas | |
CO6331430A2 (es) | Composicion farmaceutica que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/02/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/08/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |